This startup just raised US$26 million to develop safer gene editing tools
By targeting RNA rather than DNA, Amber Bio aims to treat multiple genetic diseases with fewer safety risks.
By targeting RNA rather than DNA, Amber Bio aims to treat multiple genetic diseases with fewer safety risks.